Details
Stereochemistry | ACHIRAL |
Molecular Formula | C14H22BrN3O2 |
Molecular Weight | 344.247 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN(CC)CCNC(=O)C1=CC(Br)=C(N)C=C1OC
InChI
InChIKey=GIYAQDDTCWHPPL-UHFFFAOYSA-N
InChI=1S/C14H22BrN3O2/c1-4-18(5-2)7-6-17-14(19)10-8-11(15)12(16)9-13(10)20-3/h8-9H,4-7,16H2,1-3H3,(H,17,19)
Originator
Sources: https://www.google.com/patents/US3177252
Curator's Comment: reference retrieved from www.drugfuture.com/chemdata/bromopride.html
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL339 |
|||
Target ID: GO:0004104 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7823770 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Bromopan Approved UsePrincipais: distúrbios digestivos psicossomáticos ad senectude e da estafa mental. Discinesias gastroduodenais e biliares. Colopatias espasmódicas. Enxaquecas e mal-estar de origem celíaca. Náuseas. Vômitos. Anorexia.
Particulares: exames radiológicos do tubo digestivo. Preparação de explorações endoscópicas. Vômitos anestésicos. Soluços. Meteorismo abdominal pós-operatório. Manifestações digestivas após a aplicação de radioterapia. |
PubMed
Title | Date | PubMed |
---|---|---|
Mirtazapine (Remeron) as treatment for non-mechanical vomiting after gastric bypass. | 2005 May |
|
Validated method for determination of bromopride in human plasma by liquid chromatography--electrospray tandem mass spectrometry: application to the bioequivalence study. | 2005 Sep |
|
Influence of bromopride in the prophylaxis of nausea associated with fluorescein angiography. | 2007 Jan-Feb |
|
Case-crossover study of Burkholderia cepacia complex bloodstream infection associated with contaminated intravenous bromopride. | 2010 May |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.medicinanet.com.br/bula/1015/bromopan.htm
Capsules: 40-60 mg/day
Oral solution: 40-60 mg/day (adults), 0.5-1 mg/kg (children)
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7823770
Bromopride effects on cholinesterase activity in plasma, striatum, duodenum and ileum of adult male rats were measured for drug concentrations ranging from 0.006 to 3.134 microM. Bromopride can inhibit cholinesterase activity in all tissues studied,
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
A03FA04
Created by
admin on Fri Dec 15 16:02:29 GMT 2023 , Edited by admin on Fri Dec 15 16:02:29 GMT 2023
|
||
|
NCI_THESAURUS |
C66883
Created by
admin on Fri Dec 15 16:02:29 GMT 2023 , Edited by admin on Fri Dec 15 16:02:29 GMT 2023
|
||
|
NCI_THESAURUS |
C267
Created by
admin on Fri Dec 15 16:02:29 GMT 2023 , Edited by admin on Fri Dec 15 16:02:29 GMT 2023
|
||
|
WHO-VATC |
QA03FA04
Created by
admin on Fri Dec 15 16:02:29 GMT 2023 , Edited by admin on Fri Dec 15 16:02:29 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2446
Created by
admin on Fri Dec 15 16:02:29 GMT 2023 , Edited by admin on Fri Dec 15 16:02:29 GMT 2023
|
PRIMARY | |||
|
3142
Created by
admin on Fri Dec 15 16:02:29 GMT 2023 , Edited by admin on Fri Dec 15 16:02:29 GMT 2023
|
PRIMARY | |||
|
75473V2YZK
Created by
admin on Fri Dec 15 16:02:29 GMT 2023 , Edited by admin on Fri Dec 15 16:02:29 GMT 2023
|
PRIMARY | |||
|
100000088697
Created by
admin on Fri Dec 15 16:02:29 GMT 2023 , Edited by admin on Fri Dec 15 16:02:29 GMT 2023
|
PRIMARY | |||
|
19768
Created by
admin on Fri Dec 15 16:02:29 GMT 2023 , Edited by admin on Fri Dec 15 16:02:29 GMT 2023
|
PRIMARY | RxNorm | ||
|
C013855
Created by
admin on Fri Dec 15 16:02:29 GMT 2023 , Edited by admin on Fri Dec 15 16:02:29 GMT 2023
|
PRIMARY | |||
|
BROMOPRIDE
Created by
admin on Fri Dec 15 16:02:29 GMT 2023 , Edited by admin on Fri Dec 15 16:02:29 GMT 2023
|
PRIMARY | |||
|
406
Created by
admin on Fri Dec 15 16:02:29 GMT 2023 , Edited by admin on Fri Dec 15 16:02:29 GMT 2023
|
PRIMARY | |||
|
DB09018
Created by
admin on Fri Dec 15 16:02:29 GMT 2023 , Edited by admin on Fri Dec 15 16:02:29 GMT 2023
|
PRIMARY | |||
|
4093-35-0
Created by
admin on Fri Dec 15 16:02:29 GMT 2023 , Edited by admin on Fri Dec 15 16:02:29 GMT 2023
|
PRIMARY | |||
|
C73035
Created by
admin on Fri Dec 15 16:02:29 GMT 2023 , Edited by admin on Fri Dec 15 16:02:29 GMT 2023
|
PRIMARY | |||
|
DTXSID0045383
Created by
admin on Fri Dec 15 16:02:29 GMT 2023 , Edited by admin on Fri Dec 15 16:02:29 GMT 2023
|
PRIMARY | |||
|
CHEMBL399510
Created by
admin on Fri Dec 15 16:02:29 GMT 2023 , Edited by admin on Fri Dec 15 16:02:29 GMT 2023
|
PRIMARY | |||
|
223-842-2
Created by
admin on Fri Dec 15 16:02:29 GMT 2023 , Edited by admin on Fri Dec 15 16:02:29 GMT 2023
|
PRIMARY | |||
|
m2713
Created by
admin on Fri Dec 15 16:02:29 GMT 2023 , Edited by admin on Fri Dec 15 16:02:29 GMT 2023
|
PRIMARY | Merck Index | ||
|
758391
Created by
admin on Fri Dec 15 16:02:29 GMT 2023 , Edited by admin on Fri Dec 15 16:02:29 GMT 2023
|
PRIMARY | |||
|
SUB05921MIG
Created by
admin on Fri Dec 15 16:02:29 GMT 2023 , Edited by admin on Fri Dec 15 16:02:29 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)